A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-27

Study Completion Date

2026-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial tests whether \[18F\]FluorThanatrace by positron emission tomography (PET)/computed tomography (CT) can improve imaging techniques in patients with breast cancer undergoing a standard of care biopsy or surgery. \[18F\]FluorThanatrace is a new radioactive tracer, which is a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, \[18F\]FluorThanatrace. Because some cancers take up \[18F\]FluorThanatrace it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. \[18F\]FluorThanatrace by PET/CT may help detect the activity of a certain enzyme in the body that may be related to cancer growth in patients with breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

NCT03083288

Breast Cancer

ACTIVE_NOT_RECRUITING PHASE1

FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

NCT01864083

Breast Cancer

COMPLETED EARLY_PHASE1

Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography

NCT02455453

Breast Cancer

COMPLETED PHASE2

Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer

NCT01018251

Adult Women With a New Diagnosis of Invasive Breast Cancer (Have Not Undergone Treatment)

WITHDRAWN NA

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

NCT01928186

Estrogen Receptor Positive HER2/Neu Negative Male Breast Carcinoma +7 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. Correlate \[18F\]FluorThanatrace (FTT) PET/CT uptake in patients with primary breast cancer compared to PARP1 quantitative immunohistochemistry (IHC) as the tissue reference standard.

SECONDARY OBJECTIVES:

I. Correlate \[18F\]FluorThanatrace uptake with other measures of PARP-1 activity in tumor tissue samples - quantitative IHC, immunofluorescence (IF) and \[125I\]KX1 autoradiography.

II. Determine the ranges of uptake on \[18F\]FluorThanatrace PET/CT imaging across patients with breast cancer undergoing \[18F\]FTT PET/CT.

III. Demonstrate the reproducibility of \[18F\]FTT uptake on PET/CT using test-retest imaging.

IV. Confirm the safety of \[18F\]FluorThanatrace.

OUTLINE:

Patients receive \[18F\]FTT intravenously (IV) over a few seconds to a minute and then undergo PET/CT scan over 20-30 minutes at baseline and another optional scan 1 week later. During the \[18F\]FTT PET/CT scan patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment ([18F]FTT PET/CT)

Patients receive \[18F\]FTT IV over a few seconds to a minute and then undergo PET/CT scan over 20-30 minutes at baseline and another optional scan 1 week later. During the \[18F\]FTT PET/CT scan patients.

Group Type EXPERIMENTAL

Computed Tomography

Intervention Type PROCEDURE

Undergo \[18F\]FFT PET/CT

Fluorine F 18 Fluorthanatrace

Intervention Type RADIATION

Given IV

Positron Emission Tomography

Intervention Type PROCEDURE

Undergo \[18F\]FFT PET/CT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Computed Tomography

Undergo \[18F\]FFT PET/CT

Intervention Type PROCEDURE

Fluorine F 18 Fluorthanatrace

Given IV

Intervention Type RADIATION

Positron Emission Tomography

Undergo \[18F\]FFT PET/CT

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CAT CAT Scan Computerized Axial Tomography Computerized Tomography CT CT Scan tomography [18F]FluorThanatrace [18F]FTT FLUORTHANATRACE F-18 Medical Imaging, Positron Emission Tomography PET PET Scan Positron Emission Tomography Scan Positron-Emission Tomography proton magnetic resonance spectroscopic imaging

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants will be \>= 18 years of age
* Known primary breast cancer. For subjects with primary breast cancer we will target lesion size of 1.0 cm or greater on at least one type of standard clinical imaging (e.g. mammogram, ultrasound, breast magnetic resonance imaging \[MRI\])
* A candidate for primary breast surgery (mastectomy or lumpectomy)
* Participants must be informed of the investigational nature of this study and provide written informed consent, in accordance with institutional and federal guidelines prior to study-specific procedures

Exclusion Criteria

* Females who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to injection of FTT
* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
* Current or prior therapy for the primary breast cancer
* Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes